Jiang et al. observed there was a correlation between low EPLIN transcripts and clinical outcomes in breast cancer, with reduced EPLIN transcript expression observed in tumour compared to normal tissues, in grade 2 and grade 3 cancers compared to grade 1 cancer and in TNM4 stage tumours compared to TNM1 stage tumours and low EPLIN transcript expression associated with poorer patient outlooks and reduced overall and disease-free survival [7]. The gene discussed is LIMA1; the disease is breast carcinoma.